Quality of Life and Decision Regret Risk in Graves' Disease After Radioactive Iodine Therapy: A Prospective Cohort Study
Clinical Endocrinology · 2026
DOI: 10.1111/cen.70092 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical Endocrinology, 2026. Verfasst von Qian Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, the Second Affiliated Hospital of Chengdu Medical College, China National Nuclear Corporation 416 Hospital, Chengdu, …. Hauptthemen laut MEDLINE: Graves Disease, Quality of Life, Iodine Radioisotopes, Emotions. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Sichuan provincial medical youth innovation research project, Chengdu city technology innovation and research development project, Chengdu medical research project.
Abstract (Originalsprache)
Objective
To identify pre‐treatment determinants of hypothyroidism and decision regret (DR) following radioiodine (RAI) therapy in Graves' disease (GD), and to assess their longitudinal impact on health‐related quality of life (QoL).
Methods
Prospective cohort of 500 GD patients receiving RAI. Machine learning models predicted hypothyroidism (3/6 months) and high DR using clinical indices, socio‐economic factors, and ThyPRO‐39 QoL scores. Longitudinal QoL was assessed at baseline, 3 and 6 months.
Results
Unmarried ( p < 0.001), unemployed (35.50 ± 23.15 vs. 27.01 ± 6.95; p = 0.032), and higher income patients (> 5000 CNY/month: 29.67 ± 6.94 vs. 26.10 ± 7.95; p = 0.018) had significantly higher DR. Longer pre‐RAI medication (> 12 months: 30.31 ± 15.96 vs. 27.48 ± 10.42; p = 0.015) increased regret. Hypothyroidism models showed poor discrimination (AUC ≤ 0.59). DR prediction was robust (LR AUC = 0.81), driven by pre‐treatment stress (β = 1.32, p < 0.001) and anxiety (β = 0.98, p = 0.003). QoL improved in goitre ( p < 0.001) and hypermetabolic symptoms ( p < 0.001) at 3 months, while overall QoL ( p < 0.001) and depression ( p = 0.006) improved by 6 months. Cognitive deficits persisted beyond 3 months ( p > 0.05).
Conclusion
Non‐clinical factors (marital/employment/income status) and psychological states strongly predict post‐RAI regret. Hypothyroidism remains unpredictable, but high DR risk can be accurately identified (AUC = 0.81) for targeted intervention. Persistent cognitive impairment requires clinical attention despite biochemical normalisation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, the Second Affiliated Hospital of Chengdu Medical College, China National Nuclear Corporation 416 Hospital, Chengdu, Sichuan, China.
Förderung
- Sichuan provincial medical youth innovation research project
- Chengdu city technology innovation and research development project
- Chengdu medical research project
- Clinical Scientific Research Fund of Chengdu Medical College
Zitieren
APA
Liu, Q., Luo, X., Zhou, H., Huang, Y., Xia, Y., Liu, L., Shi, Y., & Jiang, X. (2026). Quality of Life and Decision Regret Risk in Graves' Disease After Radioactive Iodine Therapy: A Prospective Cohort Study. Clinical Endocrinology. https://doi.org/10.1111/cen.70092
Vancouver
Liu Q, Luo X, Zhou H, Huang Y, Xia Y, Liu L, et al. Quality of Life and Decision Regret Risk in Graves' Disease After Radioactive Iodine Therapy: A Prospective Cohort Study. Clinical Endocrinology. 2026. doi:10.1111/cen.70092
BibTeX
@article{Liu2026,
author = {Liu, Qian and Luo, Xueying and Zhou, Huan and Huang, Ying and Xia, Yuxiao and Liu, Lina and Shi, Yuhong and Jiang, Xue},
title = {Quality of Life and Decision Regret Risk in Graves' Disease After Radioactive Iodine Therapy: A Prospective Cohort Study},
journal = {Clinical Endocrinology},
year = {2026},
doi = {10.1111/cen.70092}
}
EUVIMED